Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Rating of “Buy” by Analysts

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $22.29.

Several analysts have recently weighed in on ZVRA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Finally, Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $8.65 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The firm has a market capitalization of $472.98 million, a price-to-earnings ratio of -4.39 and a beta of 1.87. The company’s fifty day moving average is $7.59 and its two-hundred day moving average is $8.08. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same period last year, the firm earned ($0.40) EPS. Equities research analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current year.

Insider Activity at Zevra Therapeutics

In other news, Director John B. Bode bought 10,000 shares of the stock in a transaction on Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares of the company’s stock, valued at approximately $318,400. This trade represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets acquired a new position in Zevra Therapeutics during the fourth quarter worth $53,000. GAMMA Investing LLC boosted its holdings in Zevra Therapeutics by 20,564.1% during the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock worth $60,000 after purchasing an additional 8,020 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Zevra Therapeutics in the fourth quarter valued at $94,000. Squarepoint Ops LLC lifted its stake in Zevra Therapeutics by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after acquiring an additional 4,384 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new stake in Zevra Therapeutics in the fourth quarter valued at $145,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.